Conference Summaries: Day Three<BR> Wednesday, February 7, 2001

The Body Covers: The 8th Conference on Retroviruses and Opportunistic Infections

Conference Summaries: Day Three
Wednesday, February 7, 2001

Hear the Lectures from The 8th Conference on Retroviruses and Opportunistic Infections
Hear the Symposia from The 8th Conference on Retroviruses and Opportunistic Infections
Search through the conference's original abstracts

Development of CCR5 Antagonists as a New Class of Anti-HIV Therapeutic (State-of-the-Art Lecture L11)
Coverage by Paul E. Sax, M.D.
Antiretroviral Chemotherapy II (Session 60)
Coverage by Calvin Cohen, M.D.
- CD4 + Lymphocyte Level Is Better than HIV-1 Plasma Viral Load in Determining When to Initiate HAART (Slide Session 519)
- Low-Level HIV Viral Rebound and Blips in Patients Receiving Potent Antiretroviral Therapy (Slide Session 522)
Coverage by Keith Henry, M.D.
- Impact of Directly-Observed Therapy on Long-Term Outcomes in HIV Clinical Trials (Slide Session 528)
Viral Reservoirs (Session 62)
Coverage by Keith Henry, M.D.
- Host Factors in the Pathogenesis of HIV Disease: Implications for Therapeutic Strategies (S16)
- Latent Reservoir and Residual HIV-1 Replication on Antiretroviral Therapy (S17)
Metabolic Complications of HIV-1 Disease (State-of-the-Art Summary Session 64)
Coverage by Richard Alan Elion, M.D.
HCV Co-Infection (Session 68)
Coverage by Richard Alan Elion, M.D.
- Hepatitis C (HCV) Co-Infection Is Associated with Increased Morbidity and Mortality Among HIV-Infected Patients (Poster 569)
HHV-8 and Kaposi's Sarcoma (Session 70)
Coverage by Brian Boyle, M.D.
- Effect of HAART on Survival with Kaposi's Sarcoma and Non-Hodgkin's Lymphoma (Poster 589)
CNS Reservoirs (Session 75)
Coverage by Brian Boyle, M.D.
- The CSF Concentration/IC50 Ratio: A Predictor of CNS Antiretroviral (ARV) Efficacy (Poster 614)
Hyperlactatemia, Hepatotoxicity, and Other Adverse Effects of Antiretroviral Therapies (Session 76)
Coverage by Brian Boyle, M.D.
- Incidence of Pancreatitis in HIV-Infected Patients on Nucleoside RTIs. (Poster 620)
Coverage by Keith Henry, M.D.
- Epidemiological Risk Factors and Immunological Mechanisms of Hypersensitivity Reactions to Abacavir (Poster 621)
- Comparison of Symptoms of Influenza A Infection with Abacavir-Associated Hypersensitivity Reaction (Poster 622)
Coverage by Andrew T. Pavia, M.D.
- Mitochondrial and Mitochondrial-Like Symptoms in Children Born to HIV-Infected Mothers. Exhaustive Evaluation in a Large Prospective Cohort (Poster 625B)
Osteopenia and Bone Metabolism Disorders (Session 77)
Coverage by Brian Boyle, M.D.
- Increasing Incidence of Avascular Necrosis of the Hip in HIV-Infected Patients (Poster 637)
Abnormalities of Fat Distribution and Insulin Resistance (Session 79)
Coverage by Pablo Tebas, M.D.
- Does Race Protect an Asian Population from Developing Lipodystrophy in HIV-Infected Individuals on HAART? (Poster 648)
Coverage by Paul E. Sax, M.D.
- Nevirapine Containing Potent Antiretroviral Therapy Results in Ananti-Atherogenic Plasma Lipid Profile: Results from the Atlantic Trial (Poster 654B)
Cardiovascular Disease Risk (Session 80)
Coverage by Benjamin Young, M.D.
- Do Protease Inhibitors Increase the Risk for Coronary Heart Disease Among HIV-Positive Patients-Follow-Up Through June 2000 (Poster 655)
Coverage by Richard Alan Elion, M.D.
- ACTG 5056: Metabolic Status and Cardiovascular Disease Risk for a Cohort of HIV-1-Infected Persons Durably Suppressed on an Indinavir-Containing Regimen (ACTG 372A) (Poster 656)
Antiretroviral Switch Studies for Metabolic Complications (Session 82)
Coverage by Paul E. Sax, M.D.
- An Open Randomized Study on the Replacement of HIV-1 Protease Inhibitors by Efavirenz in Chronically Suppressed HIV-1-Infected Patients with Lipodystrophy (Poster 668)
- SWATCH Study: A Multicenter Trial of Proactive Treatment Switching. Results at Nine Months of Follow-Up. (Poster 669)
Coverage by Keith Henry, M.D.
- Metabolic and Clinical Evaluation of Lipodystrophy Syndrome (LD) in HIV-1-Infected Adults Receiving Initial HAART with or without a Protease Inhibitor (PI): 48-Week Data from the CNAF3007 Study (Poster 670)
Coverage by Benjamin Young, M.D.
- Long-Term Efficacy and Tolerance of Switching the Protease Inhibitor for Non-Nucleoside Reverse Transcriptase Inhibitors: A 52-Week, Multicenter, Prospective Study (Poster 673)
Antiretroviral Therapy in Treatment-Naive and -Experienced Children (Session 84)
Coverage by Paul E. Sax, M.D.
- Is Simplification of HAART Safe in HIV-Infected Children? First Pediatric Switch Study (Poster 679)
Coverage by Judith Feinberg, M.D.
- Virologic and Immunologic Responses in Children with Advanced HIV Disease on a New HAART Regimen (PACTG 366) (Poster 684)
Immune Reconstitution in Children (Session 85)
Coverage by Keith Henry, M.D.
- HIV-Infected Children on HAART Reconstitute Tetanus-Specific T Cell Responses without Booster Vaccination (Poster 688)
Perinatal Transmission: Trends in Use of Preventive Interventions (Session 86)
Coverage by Andrew T. Pavia, M.D.
- Maternal ART Use During Pregnancy and Maternal or Pregnancy Outcomes (Poster 699)
- Have Pregnancy Rates in Human Immunodeficiency Virus-Infected Women Changed in the Era of Effective Antiretroviral Therapy for Prevention of Perinatal Transmission? (Poster 700)
Drug-Drug Interactions (Session 92)
Coverage by Andrew T. Pavia, M.D.
- Amprenavir (APV) and Ritonavir (RTV): Intra-Individual Comparison of Different Doses and Influence of Concomitant NNRTI on Steady-State Pharmacokinetics in HIV-Infected Patients (Poster 739)
Coverage by Pablo Tebas, M.D.
- Garlic Supplements Decrease Saquinavir Plasma Concentrations (Poster 743)
Coverage by Benjamin Young, M.D.
- Short-Term Safety of Cannabinoids in HIV Patients (Poster 744)
- The Pharmacokinetic (PK) Effects of Marijuana (THC) on Nelfinavir (NFV) and Indinavir (IDV) (Poster 745)
Pharmacokinetics of Antiretroviral Drugs (Session 93)
Coverage by Andrew T. Pavia, M.D.
- Intracellular Carbovir Triphosphate (CBVTP) Levels among Patients Taking Abacavir (ABC) Once Daily (Poster 746)
Coverage by Pablo Tebas, M.D.
- The Effect of Hydroxyurea (HU) on Intracellular Deoxy- and Dideoxynucleoside Triphosphate Ratios in Naive Subjects Receiving ZDV, ABC, 3TC+- NVP over 48 Weeks -- CHARM Phosphorylation Substudy (Poster 747)
Coverage by Judith Feinberg, M.D.
- Efavirenz (EFV)-Containing Antiretroviral (ARV) Therapy (T) Effectively Reduces HIV RNA in the Seminal Plasma (SP) of HIV-1-Infected Men (M) (Poster 750)
Primary Infection (Session 94)
Coverage by Pablo Tebas, M.D.
- Low Lymph Node Viral Load Despite High Viremia in Seroconverters Supports Early HAART Intervention (Slide Session 758)

Previous Day's Sessions | Next Day's Sessions

Return to The Body's coverage of
The 8th Conference on Retroviruses and Opportunistic Infections.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.